Follow
Tumor heterogeneity
Tumor heterogeneity describes differences between tumors. Tumor heterogeneity can refer to differences between (1) tumors in different patients, (2) cancer cells in an individual patient's tumor, or (3) a primary and metastatic tumor. Understanding the heterogeneity of a tumor can facilitate diagnosis and treatment.
MAY 16, 2023 | 8:00 AM
The therapeutic use of chimeric antigen receptor T cells has achieved significant success in the treatment of B cells malignancies. Despite promising results in mouse tumor models, a similar...
MAR 30, 2023 | 12:05 PM
C.E. CREDITS
In this study, we evaluated the concordance of targeted sequencing results between paired ctDNA and tumor samples from early breast cancers scheduled for curative surgery with or without adj...
MAR 30, 2023 | 12:05 PM
In this study, we evaluated the concordance of targeted sequencing results between paired ctDNA and tumor samples from early breast cancers scheduled for curative surgery with or without adj...
MAR 08, 2023 | 1:30 PM
C.E. CREDITS
Spatial mapping of pain-associated G-Protein coupled receptors and bio-marker localization in mouse brain using RNAscope HiPlex v2 and RNA-Protein Co-Detection Assays....
MAR 01, 2023 | 8:00 AM
Date: March 01, 2023 Time: 8:00am (PST), 11:00am (EST), 5:00pm (CET) Characterizing metastasis remains key for understanding and eradicating cancer. The study of circulating tumor cells (CTC...
OCT 26, 2022 | 8:00 AM
Date: October 26, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors. Advances in technology in the pa...
AUG 16, 2022 | 11:00 AM
Date: August 16, 2022 Time: 11:00am (PDT), 2:00pm (EDT), 8:00pm (CEST) Understanding genomic variation in the context of cancer is paramount to identifying disease drivers and informing pers...
MAY 25, 2022 | 10:00 AM
Date: May 25, 2022 Time: 10:00am (PDT), 1:00pm (EDT), 7:00pm (CEST) Programmable RNA base editors are excellent tools to modify RNA transcripts at precise locations or designated hotspots. P...
DEC 07, 2021 | 10:00 AM
Date: December 07, 2021 Time: 10:00am (PST) The RNAscope™ technology allows high sensitivity and spatial resolution providing pivotal single-cell information to gain better insights in...
NOV 17, 2021 | 8:00 AM
Date: November 17, 2021 Time: 8:00am (PDT), 11:00am (EDT) From waste disposal to promising biomarkers and therapeutic agents, exosomes and other extracellular vesicles are valuable in resear...
OCT 26, 2021 | 8:00 AM
Date: October 26, 2021 Time: 8:00am (PDT), 11:00am (EDT) A complex interaction among heterogenous immune and tumor cells within the tumorous tissue not only influences tumor progression, but...
OCT 06, 2021 | 9:00 AM
Background: Localized prostate cancer is notable for tumor heterogeneity, and immune heterogeneity within tumor versus benign areas. B7-H3, a member of the B7 superfamily, is highly expresse...
SEP 23, 2021 | 8:00 AM
Date: September 23, 2021 Time: 8:00am (PDT), 11:00am (EDT) The tumor microenvironment (TME) comprises complex cellular and structural features. The processes and interactions within the TME...
SEP 22, 2021 | 6:00 AM
Extracellular vesicles provide a tool to measure tumour characteristics in blood, at various stages of cancer development. We have extensively used multiplex RNA bead-based assays (Quantigen...
AUG 24, 2021 | 8:00 AM
Date: August 24, 2021 Time: 8:00am (PST), 11:00am (EST) Liver cancer is the third cause of cancer-related mortality worldwide. Most patients have chronic liver disease, which has allowed...
JUN 17, 2021 | 7:00 AM
DATE: June 17, 2021 TIME: 07:00am PDT Colorectal cancer is a particularly challenging disease for immunotherapy given tumor heterogeneity. Multiplexed whole slide imaging allows deep context...
JUN 08, 2021 | 10:00 AM
Date: June 8, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Most deaths from ovarian and endometrial cancer are due to high-grade subtypes that metastasize before they are detectable by available...
JUN 02, 2021 | 12:00 AM
Chimeric antigen receptor (CAR) T cells have demonstrated significant success in treating relapsed or treatment-refractory hematologic malignancies in the clinic, inducing remissions in 70-9...
MAY 26, 2021 | 9:00 AM
Date: May 26, 2021 Time: 9:00am (PDT), 12:00pm (EDT) Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors but is challenged in that only a minority of patie...